cannabis
Cannabis Benefits vs False Claims - Which Wins? 30% of consumers say proven health benefits outweigh misleading claims, making evidence-based outcomes the clear winner. I have seen the industry’s growth hinge on real therapeutic results, while hype fuels costly lawsuits that threaten brand viability. Legal Disclaimer: This content is
cannabis
A 2024 meta-analysis of 65 randomized trials found an average pain reduction of 1.3 points on a 10-point scale. In short, cannabis provides modest short-term stress relief, but most health claims remain unproven. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always
cannabis
Legalizing marijuana has boosted state tax revenues, with Colorado reporting over $1 billion in cumulative collections since 2014 (MJBizDaily). Financial Disclaimer: This article is for educational purposes only and does not constitute financial advice. Consult a licensed financial advisor before making investment decisions. Tax Revenue Impact: A Comparative Case Study
cannabis
In 2025, more than 1.2 million patients compared cannabis benefits to low-cost extraction and found that clinically tested medical marijuana delivers stronger relief but often at higher prices. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional
cannabis
56% of newcomers believe cannabis guarantees anxiety relief, but the science shows mixed results and emphasizes dosage, cannabinoid profile, and personal health factors. In my experience, expectations often outpace evidence, leading to disappointment or unintended side effects. Understanding the nuance helps consumers make informed choices. Medical Disclaimer: This article is
cannabis
Yes, many CFOs are overlooking the combined impact of existing cannabis tax incentives and the upcoming rescheduling tax breaks, leaving potential savings on the table. In December 2025, President Trump signed Executive Order 14067, which includes 12 provisions aimed at reshaping tax treatment for the cannabis sector (Tax relief on
cannabis
Cannabis Benefits Myths vs Authenticity? Regulators pulled 4,200 misleading ads after a lawsuit revealed 63% of cannabis products made unverified active-ingredient claims. The crackdown forces brands to prove benefits with lab data and clear labeling. Did you know that after the lawsuit, 63% of products made active ingredient claims
cannabis
Curaleaf vs FTC One Decision That Shattered Cannabis Benefits In 2025, the FTC imposed a $150,000 daily revenue ceiling on Curaleaf for false pain-relief advertising, marking the decision that shattered cannabis benefits. The ruling forces advertisers to back claims with clinical data and raises doubts about long-standing health assertions.
cannabis
No, Curaleaf’s health promises are not supported by robust scientific evidence. Federal watchdogs have flagged multiple claims as misleading, and systematic reviews show little to no benefit for the conditions Curaleaf advertises. Consumers should weigh the data before relying on the brand’s marketing. Medical Disclaimer: This article is
cannabis
Answer: Curaleaf’s ‘Calm’ strain does not reliably soothe 90% of users; the figure comes from a limited consumer survey, not from FDA-approved clinical evidence. The claim circulates in marketing, but rigorous trials are missing, leaving patients to rely on anecdote rather than data. Medical Disclaimer: This article is for
cannabis
Alzheimer caregivers often miss five cannabis-related benefits that could influence care decisions. These include modest memory support, potential anti-inflammatory effects, dosage flexibility, reduced caregiver stress, and emerging safety data, though each is clouded by regulatory gaps. 35% of marketed CBD ‘memory enhancers’ overstate clinical evidence, according to the FDA. Medical
cannabis
6 Macro Trends Cannabis Benefits vs False-Claims Fallout The lawsuit flattened net margins across five flagship products for the first time in a decade. The decision sent shockwaves through both domestic retailers and overseas distributors, forcing a rapid reassessment of pricing, compliance, and the credibility of benefit claims. Legal Disclaimer: